Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
UNLIMITED Watchlists, Portfolios, Screeners, and other Barchart tools with Barchart Premier. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Avacta Group Plc (AVCT.LN)

Avacta Group Plc (AVCT.LN)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [LSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [LSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Profile for [[ item.sessionDateDisplayLong ]]

Company Info

Avacta Group Plc 58 Wood Lane White City Imperial College Campus London W12 7RZ GBR

https://avacta.com P: 203-911-0353

Sector:

N/A

INDUSTRY GROUPING:

N/A

Description:

Avacta Group PLC is a clinical-stage life sciences company expanding the reach of potent cancer therapies with the pre-CISION platform. pre-CISION is a proprietary warhead delivery system based on a tumor-specific protease (fibroblast activation protein or FAP) that is designed to concentrate potent warheads in the tumor microenvironment while sparing normal tissues. The company's pipeline consists of pre-CISION peptide drug conjugates (PDC) or Affimer drug conjugates (AffDC) that leverage the tumor-specific release mechanism, providing benefits over traditional antibody drug conjugates. The firm has one reportable segment, Therapeutics, which is engaged in the development of novel cancer therapies harnessing its proprietary technology. Geographically, it derives revenue from South Korea.

Key Statistics

Overview:

Market Capitalization, $K 342,594
Shares Outstanding, K 433,663
Annual Sales, $ 113 K
Annual Net Income, $ -52,841 K
% of Insider Shareholders 51.35%
% of Institutional Shareholders 13.45%

Growth:

1-Year Return 36.84%
3-Year Return -36.06%
5-Year Return -39.24%
5-Year Revenue Growth -48.47%

Per-Share Information:

Next Earnings Date N/A
Earnings Per Share ttm -0.18
Dividend Payout Ratio 0.00%
Most Recent Split 1-100 on 01/26/16

AVCT.LN Ratios

Ratio
Price/Earnings ttm N/A
Price/Earnings forward N/A
Return-on-Equity % -259.20%
Return-on-Assets % -105.63%
Profit Margin % -46,761.95%
Debt/Equity 0.16
Price/Sales 2,598.95
Price/Book 2,379.13
Book Value/Share 0.00
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar